Stocks in play: WPD Pharmaceuticals Inc.

Announced that it has engaged Image Analysis Group, a leading medical imaging company, to provide important critical imaging services during the Berubicin phase 2 clinical trials which are scheduled to start in February 2021. IAG has deep expertise in partnering with global biotech companies to provide centralized reading and analysis of patient responses in real time. IAG’s scientific and clinical imaging expertise in the field of glioblastoma multiforme, coupled with IAG’s proprietary Artificial Intelligence (AI) powered platform DYNAMIKA will allow WPD and its partners to review efficacy assessments, objective responses, and to thoroughly explore Berubicin’s effect in patients with GBM. WPD Pharmaceuticals Inc. shares C.WBIO are trading unchanged at $0.32.

Read:

• The Plant-Based Revolution is Creating Big Opportunity for These Companies

• The $120 Trillion Investment Trend Transforming Wall Street

• Psychedelics Legalization Efforts Quickly Gaining Momentum